Francisco Ujueta/LinkedIn;
Eric A Secemsky/LinkedIn
Apr 12, 2026, 13:44
Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
Francisco Ujueta, Vascular Cardiologist at Vanderbilt University Medical Center, shared a post on LinkedIn about a recent article he and his colleague co-authored, adding:
“View our commentary on differences in PAD and CAD – emphasizing higher ischemic and bleeding risks, greater heterogeneity, and the need for individualized antithrombotic strategies.”
Title: Too much, too little, or just right: Tailoring postrevascularization antithrombotic therapy in PAD versus CAD when one size does not fit all
Authors: Francisco Ujueta, Eric A Secemsky
Read the Full Article on Vascular Medicine
Stay updated with Hemostasis Today.
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026